



Ciprofloxacin/amikacin combination therapy: evaluation in biofilms of *Pseudomonas aeruginosa* overproducing efflux pumps

A. Soares, K. Alexandre, L. Lemée, F. Caron, M. Pestel-Caron, M. Etienne

► To cite this version:

A. Soares, K. Alexandre, L. Lemée, F. Caron, M. Pestel-Caron, et al.. Ciprofloxacin/amikacin combination therapy: evaluation in biofilms of *Pseudomonas aeruginosa* overproducing efflux pumps. 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2019), Apr 2019, Amsterdam, Netherlands. . hal-02264261

HAL Id: hal-02264261

<https://normandie-univ.hal.science/hal-02264261>

Submitted on 6 Aug 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Introduction

- Eradicating biofilm-related infections without mechanical biofilm dispersal remains a challenge
- The contribution to tolerance of low-level resistance related to the over-expression of efflux systems has not been evaluated in biofilms
- **Combination therapies are still considered as an approach to enhance killing of biofilm-embedded cells and minimize the emergence of resistance**

❖ Objectives:

Efficacy of ciprofloxacin and amikacin used separately and in combination, against *P. aeruginosa* planktonic and biofilm cultures

Impact of efflux systems on antibiotic (ATB) efficacy in planktonic and biofilm cultures

Methods

- ❖ PAO1, a wild type clinical strain (WT), and 3 clinical strains overexpressing the efflux MexAB-OprM (AB), MexXY-OprM (XY) and MexCD-OprJ (CD)
- ❖ Planktonic and 2-day-old biofilm (6-wells plate) cultures of *P. aeruginosa*
 - challenged with **ciprofloxacin (4 mg/L)** and **amikacin (40 mg/L)** separately, in combination, and successively
- ❖ Number of viable and resistant cells determined on MH2 without ATB and supplemented with 4-fold MIC of ciprofloxacin or amikacin
- ❖ **Characterization of resistant mutants** = ATB susceptibility, QRDR sequencing, and efflux pumps gene expression
- ❖ Determination of ciprofloxacin and amikacin **group’s MICs** (by recovering surviving cells from biofilms on MH2 plates after 72 h of ATB exposure)
- ❖ Measurement of ciprofloxacin and amikacin concentrations in the biofilm at the end of the ciprofloxacin and amikacin exposure

Results

❖ Strains

Table 1. Main characteristics of the strains used.

	MIC (mg/L)				Mutation frequency	Mean relative gene expression		
	TICM (S≤16 -R>16)	CIP (S≤0.5 -R>0.5)	LVX (S≤1 -R>1)	AMK (S≤8 -R>16)		mexB	mexY	mexC
PAO1	16	0.125	0.25	2	1.8 x 10 ⁻⁸	1.0	1.0	1.0
WT	16	0.06	0.25	2	3.4 x 10 ⁻⁹	1.7	1.1	0.3
AB	>256	0.06	1	2	8.1 x 10 ⁻⁹	3.6	5.3	0.7
CD	4	0.5	4	0.5	3.5 x 10 ⁻⁸	1.3	1.7	14.6
XY	32	0.125	1	16	2.9 x 10 ⁻⁹	1.3	10.1	4.1

S, susceptible; R, resistant; TICM, ticarcillin/clavulanate; CIP, ciprofloxacin; LVX, levofloxacin; AMK, amikacin

- PAO1, WT, AB, and CD were susceptible to ciprofloxacin and amikacin
- **XY strain was intermediate to amikacin (CMI = 16 mg/L)**
- No mutation in the QRDR
- No hypermutable strains
- AB, CD and XY respectively overexpressed MexAB-OprM, MexCD-OprJ and MexXY-OprM

❖ Planktonic time-kill assay




Figure 1. Planktonic time-kill assays with ciprofloxacin (a), amikacin (b) and the combination of ciprofloxacin and amikacin (c). The total cfu numbers are the mean value for three different experiments. GC: growth control

- ≥3 log₁₀ cfu/mL reduction after 4 h of ciprofloxacin or amikacin in all strains
- Regrowth of high-level resistant mutants:
 - when CD was exposed to ciprofloxacin (mutations in the QRDR of GyrA [Thr-83->Ile] and ParC [Ser-80->Leu])
 - when XY was exposed to amikacin
- **Eradication with a ciprofloxacin + amikacin combination in XY and CD strains**
- Eradication with ciprofloxacin or amikacin in all the other strains

❖ Biofilm time-kill assay




Figure 2. Biofilm time-kill assays with ciprofloxacin, amikacin and the combination of ciprofloxacin and amikacin. The total cfu numbers are the mean value for three different experiments. GC, growth control; CIP, ciprofloxacin; AMK, amikacin

- ≥3 log₁₀ cfu/mL reduction in all strains after 8 h of ATB exposure (similar killing rates for all regimens [p>0.05])
- 4 [3.62 – 4.17] log₁₀ cfu/mL plateau in all strains and for all regimens after 8 h and until 72 h of ATB exposure

- ❑ **No MIC creep** : group’s MICs for the surviving cells after 72 h of ATB exposure **unchanged compared to pre-exposure MIC**
- ❑ Erratically, for all regimens including combination therapy, 4-fold MIC ciprofloxacin or amikacin resistant mutants isolated from detached biofilm: low density, no mutation in the QRDR, and **no bacterial regrowth**
- ❑ **Sequential ATB exposure**: bacterial reduction after the first ATB exposure significantly higher than after the second ATB exposure (p<0.05)
- ❑ **Stable ATB concentrations along time**: no ATB degradation according ciprofloxacin and amikacin concentration measurements

Conclusion

- ❖ **The ciprofloxacin-amikacin combination enhances killing and prevents emergence of resistance for low-level resistant strains in planktonic cultures, but not in biofilm.**
- ❖ The low-level resistance conferred by MexCD-OprJ and MexXY-OprM efflux pumps may reduce intracellular antibiotic concentrations and hence facilitate the selection of high-level resistant mutants by target site mutations ,
 - In planktonic conditions, we suggest that the **MIC value of ciprofloxacin** should be determined, and **levofloxacin evaluated**, in order to detect MexCD-OprJ overexpression.
- ❖ **In biofilm, the lack of bacterial eradication was related to an antibiotic-recalcitrant population composed of persister cells, refractory to antibiotics used alone or in combination.** No regrowth due to high-level resistant mutant was detected whatever the antibiotic/strain pair studied.